Europe’s CBD Market Is Growing — But Regulatory Fragmentation and Payment Access Are Choking Brands
Affiliate Disclosure: This article contains affiliate links. We may earn a commission if you purchase through links on this page, at no additional cost to you.
Europe’s CBD market is expanding despite a regulatory framework that remains, in meaningful ways, unresolved. Ingestible CBD products continue to sell across EU member states under varying enforcement postures even as Novel Food authorization — the legal prerequisite for approved market access — has yet to be granted for any CBD product at the EU-wide level. The disconnect between commercial reality and formal regulatory status is defining the European market’s 2026 trajectory.
Industry projections for the EU CBD market through 2025–2030 indicate sustained growth, driven by consumer demand for non-intoxicating plant-based wellness products in markets where cannabis remains culturally and clinically distinct from pharmaceutical options. But that growth is being structurally constrained by two forces: EFSA’s updated safety posture and persistent problems with payment processing access.
The Novel Food Problem Hasn’t Gone Away
Ingestible CBD products — oils, tinctures, capsules, gummies, beverages — remain classified as Novel Foods under EU Regulation 2015/2283. That classification requires any brand seeking to legally market these products across EU member states to submit and successfully complete a Novel Food authorization dossier — a process that is expensive, slow, and that no CBD product has yet completed at the EU-wide level.
In the absence of formal authorization, enforcement varies dramatically by country. Some EU member states — notably Germany and Switzerland — have tolerated ingestible CBD sales while authorization processes are pending. Others have taken more restrictive positions. The result is a fragmented market where the same product may be freely sold in one country and seized at the border of another.
EFSA’s February 2026 update, which set a provisional safe intake level of approximately 2 mg per day for adults, has given national enforcement agencies a reference point they’ve been using to justify tightening oversight of high-dose ingestible products. For a category in which 10 to 50 mg per serving is standard commercial dosing, the practical effect is to increase compliance risk for the mainstream product formats that drive most EU market volume.
Topicals Are the Exception
One part of the European CBD market is navigating 2026 with relative regulatory stability: topical and cosmetic CBD products. Because these fall under EU cosmetics regulations rather than Novel Food rules, they face a less restrictive compliance pathway. The enforcement gap between ingestible and topical CBD is widening, pushing some brands to shift their EU product emphasis toward cosmetics and skincare.
For companies that entered the EU market primarily through CBD-infused skincare, body care, and topical wellness products, this is a structural advantage. For brands built around consumable formats, the topicals pivot may be viable in some cases but doesn’t solve the underlying business model challenge of building revenue around products that can’t be legally marketed through mainstream EU retail channels.
Payment Processing: A Hidden Structural Barrier
Beyond product regulation, CBD brands operating in Europe face a persistent operational challenge that rarely makes headlines but fundamentally constrains growth: payment processing access. Major card networks and many acquiring banks continue to classify CBD as a high-risk category, requiring brands to use specialized high-risk merchant accounts that charge elevated transaction fees, impose reserve requirements, and offer less reliability than standard business payment infrastructure.
The problem is more acute for smaller independent brands than for well-capitalized companies with legal and financial teams capable of navigating complex merchant agreements. For the longtail of European CBD brands — the regional and single-market operators that make up the majority of the market by number — payment processing costs can represent a meaningful drag on already thin margins.
What the Market Looks Like in 2026
Despite these headwinds, the European CBD market is not contracting — it is segmenting. Brands with Novel Food dossiers in progress, compliant labeling, and products positioned within or close to EFSA’s provisional safety parameters are gaining shelf space at mainstream retailers as those retailers reduce exposure to less-documented products. Topical categories are growing. Premium, third-party tested brands are capturing share from the informal end of the market.
The long-term market case remains intact. The short-term operating environment rewards compliance infrastructure, legal patience, and product formats that navigate the regulatory landscape more cleanly than high-dose ingestibles.
This article is for informational purposes only and does not constitute medical or legal advice. CBD products have not been evaluated by the Food and Drug Administration for the diagnosis, treatment, prevention, or cure of any disease or condition. Consult a qualified professional before using any CBD or hemp-derived product.
Learn more:
